Cynril

Cynril is a fentanyl citrate formulation developed by Fontus Health for the management of breakthrough cancer pain in patients who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. As a potent opioid receptor agonist, fentanyl citrate primarily targets the mu-opioid receptor in the central nervous system, providing rapid analgesia. The drug is administered as a compressed lozenge via the oral transmucosal route, allowing for fast absorption through the buccal mucosa and bypassing first-pass metabolism to address transitory exacerbations of pain. It is available in multiple strengths ranging from 200 to 1600 micrograms to allow for individual titration.

Brand names

Cynril

Other names

fentanyl citratefentanyl citrate lozenge